Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(0)
•••
Post by funfinderon Jan 04, 2011 4:33pm
896 Views
Post# 17924168

intresting trades lots of buying at market

intresting trades lots of buying at market01/04/11 12:52:01 2.42 2.41 2.42 100
01/04/11 12:52:01 2.42 2.41 2.43 0
01/04/11 12:52:01 2.42 2.41 2.42 0
01/04/11 13:06:05 2.43 2.41 2.43 4700
01/04/11 13:06:05 2.43 2.42 2.43 0
01/04/11 13:14:48 2.44 2.42 2.43 2376
01/04/11 13:20:59 2.43 2.42 2.43 200
01/04/11 13:23:05 2.43 2.42 2.43 1600
01/04/11 13:27:29 2.43 2.42 2.43 2000
01/04/11 13:32:46 2.44 2.42 2.43 3400
01/04/11 13:34:56 2.42 2.41 2.42 3000
01/04/11 13:36:42 2.41 2.41 2.42 6600
01/04/11 13:36:55 2.41 2.41 2.42 300
01/04/11 13:37:42 2.40 2.39 2.40 1500
01/04/11 13:42:46 2.40 2.39 2.40 900
01/04/11 13:43:10 2.40 2.39 2.40 900
01/04/11 13:43:40 2.40 2.39 2.40 300
01/04/11 13:44:22 2.40 2.39 2.40 600
01/04/11 13:44:58 2.40 2.39 2.40 1600
01/04/11 13:45:31 2.40 2.39 2.40 1100
01/04/11 13:46:08 2.40 2.39 2.40 3000
01/04/11 13:46:44 2.41 2.40 2.41 2100
01/04/11 13:47:16 2.42 2.41 2.42 1200
01/04/11 13:47:54 2.42 2.41 2.42 1700
01/04/11 13:48:28 2.43 2.42 2.43 1900
01/04/11 13:49:02 2.43 2.42 2.43 2000
01/04/11 13:49:36 2.43 2.42 2.43 1900
01/04/11 13:50:10 2.43 2.42 2.43 1700
01/04/11 13:50:52 2.43 2.42 2.43 2300
01/04/11 13:51:22 2.43 2.42 2.43 1600
01/04/11 13:51:56 2.43 2.42 2.43 2900
01/04/11 13:52:34 2.43 2.42 2.43 200
01/04/11 13:53:13 2.43 2.42 2.43 1600
01/04/11 13:53:52 2.43 2.42 2.43 2000
01/04/11 13:54:22 2.43 2.42 2.43 1600
01/04/11 13:54:58 2.43 2.42 2.43 1800
01/04/11 13:55:01 2.43 2.42 2.43 200
01/04/11 13:55:01 2.43 2.42 2.43 20
01/04/11 13:58:45 2.43 2.42 2.43 164
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities